2025-12-22 - Analysis Report
Okay, here's a comprehensive report on Northrop Grumman Corp. (NOC), analyzing the provided data.

**1) Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Northrop Grumman Corp. is a global aerospace and defense technology company.
*   **Cumulative Return:** NOC's cumulative return (47.50%) underperformed the S&P 500 (VOO) cumulative return (100.88%) significantly.
*   **Divergence:** The current divergence is -53.4. This means NOC has significantly underperformed VOO during the observation period.  The relative divergence of 5.2 suggests that the current divergence is near the bottom end of its historical range relative to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 46.0% | 65.6% | 17.0% | 0.0 | 43.9 |
| 2016-2018  | -2.0% | 74.3% | -17.0% | 0.0 | 35.1 |
| 2017-2019  | 17.0% | 79.2% | -5.0% | 0.9 | 49.2 |
| 2018-2020  | -28.0% | 79.9% | -52.0% | 0.8 | 43.6 |
| 2019-2021  | 43.0% | 79.9% | -4.0% | 0.8 | 55.4 |
| 2020-2022  | 18.0% | 79.9% | 19.0% | 0.3 | 78.1 |
| 2021-2023  | 24.0% | 82.7% | 23.0% | 0.2 | 67.0 |
| 2022-2024  | -15.0% | 82.7% | -36.0% | 0.2 | 67.2 |
| 2023-2025  | -3.0% | 82.1% | -68.0% | 0.1 | 81.4 |

*   **Analysis:**

    *   **Alpha:** Alpha measures the excess return of an investment relative to the market benchmark (S&P 500).  NOC has shown fluctuating Alpha, with periods of outperformance (e.g., 2015-2017, 2020-2022, 2021-2023) and significant underperformance (e.g., 2018-2020, 2022-2025). The recent negative Alphas are concerning.
    *   **Beta:** Beta measures the volatility of a stock relative to the market.  NOC's Beta is generally low, but a beta of 0 indicates that it's less sensitive to market movements than the S&P 500.
    *   **CAGR and MDD:** NOC's has high MDD, but relatively unstable CAGR.
    *   **Cap:** The market capitalization of NOC is steadily increasing, which is generally a positive indicator for the company.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** \$568.46
*   **Last Market Change:** Price increased $1.6.
*   **Moving Averages:**
    *   5-day SMA: \$567.34
    *   20-day SMA: \$560.77
    *   60-day SMA: \$581.32

*   **Analysis:** The 5-day SMA is above the 20-day SMA, suggesting a short-term uptrend. However, the 60-day SMA is significantly higher, indicating the price may be facing resistance at that level or a longer-term downtrend.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 65.35 (Approaching overbought territory (above 70), but not there yet)
*   **PPO:** 0.39 (Positive, indicating a potential uptrend, but relatively small)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Dividend_2.31 Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -0.5 (Negative, indicating a short-term decline in relative performance)
*   **Expected Return:** -151.2% (Very Negative, suggests significant underperformance compared to the S&P 500 over the long term)

*   **Analysis:** The MRI suggests a medium-risk investment. The RSI and PPO provide conflicting signals, with the RSI edging towards overbought and the PPO hinting at a small uptrend. The Hybrid Signal suggests to Buy 100% of cash. However, the drastically negative expected return is a major red flag and indicates the data provider's models suggest significant underperformance in the future.

**4) Recent News & Significant Events**

*   **Positive:**
    *   Northrop Grumman Secured a $100M Missile Weapon System Contract.
    *   Analysts' Optimism Growing.
    *   Brokerages Giving "Moderate Buy" Recommendation.
*   **Neutral/Mixed:**
    *   Taking Stock of Valuation After Strong Year-to-Date Share Price Run.
*   **Potentially Concerning:**
    *   Assessing Value After Recent 5% Pullback in Share Price.
    *   Earnings Release Date Announcement (the impact depends on actual results).

*   **Analysis:** The news is mixed. The contract win and analyst optimism are positive. However, the article highlighting the 5% pullback and valuation concerns warrant further investigation.

**4-2) Analyst Opinions**

*   **Consensus:**
    *   Key: Buy
    *   Mean (1=StrongBuy~5=Sell): 2.04 (~Buy)
    *   Opinions: 21
    *   Target Price (avg/high/low): 662.68 / 770.00 / 533.00
    *   Recent Rating Changes: Not Provided

*   **Analysis:** The analyst consensus is "Buy" with a mean rating suggesting a moderate buy recommendation. The average target price of $662.68 suggests potential upside from the current price of $568.46.

**5) Recent Earnings Analysis**

| 날짜        | EPS  | 매출       |
| ----------- | ---- | ---------- |
| 2025-10-21 | 7.69 | 10.42 B$   |
| 2025-07-22 | 8.17 | 10.35 B$   |
| 2025-04-22 | 3.33 | 9.47 B$    |
| 2024-10-24 | 7.02 | 10.00 B$   |
| 2025-10-21 | 7.02 | 10.00 B$   |

*   **Analysis:** Revenue has been relatively stable, but EPS has fluctuated. The dip in EPS for 2025-04-22 is a point of concern and should be further investigated. The duplicate entry for 2025-10-21 with the same EPS and Revenue as 2024-10-24 appears to be an error.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | --------------- |
| 2025-09-30 | \$10.42B | 21.37%          |
| 2025-06-30 | \$10.35B | 21.35%          |
| 2025-03-31 | \$9.47B  | 16.69%          |
| 2024-12-31 | \$10.69B | 18.08%          |
| 2024-09-30 | \$10.00B | 21.07%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
| ------------ | ---------- | ----- |
| 2025-09-30 | \$15.99B | 6.88% |
| 2025-06-30 | \$15.47B | 7.59% |
| 2025-03-31 | \$14.98B | 3.21% |
| 2024-12-31 | \$15.29B | 8.27% |
| 2024-09-30 | \$14.75B | 6.96% |

*   **Analysis:**
    *   Revenue has been fairly consistent.
    *   Profit Margin has seen some fluctuation, dipping significantly in 2025-03-31.
    *   Equity is generally increasing.
    *   ROE has fluctuated, with a significant drop in 2025-03-31, coinciding with the lower profit margin in that quarter. This warrants further investigation into the cause of these fluctuations.

**7) Comprehensive Analysis**

*   **Summary:**  NOC has underperformed the S&P 500 significantly. While recent news and analyst ratings are generally positive, some concerning trends emerge. The negative Alpha values, combined with fluctuating EPS, Profit Margin and ROE, and the drastically negative Expected Return warrant caution.
*   **Key Concerns:**
    *   **Underperformance:** The significant underperformance compared to the S&P 500 is a major concern.
    *   **Fluctuating Profitability:** The changes in EPS, Profit Margin, and ROE need to be investigated to understand the underlying causes.
    *   **Negative Expected Return:** The model predicting a very large negative expected return is a strong indicator that the stock may be overvalued or facing significant headwinds.
*   **Positive Signs:**
    *   **Analyst Ratings:** The consensus "Buy" rating and target price suggest potential upside.
    *   **New Contracts:** Securing new contracts is a positive sign for future revenue.
*   **Recommendation:**  While some positive indicators exist, the negative aspects outweigh them. Before making any investment decision, further in-depth analysis is strongly recommended, focusing on the reasons for the underperformance, the fluctuations in profitability, and the factors driving the negative expected return. A closer look at the company's financial statements and industry trends is necessary.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.